BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas

Qingguo Yan1, Yuanxue Huang, A James Watkins

  • 1Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK.

Haematologica
|November 22, 2011
PubMed

Insights

Genetic changes in NF-κB regulators like A20 and MYD88 are implicated in splenic marginal zone lymphoma pathogenesis. These mutations suggest the toll-like receptor and B-cell receptor pathways are key in this lymphoma.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The genetic basis and development of splenic marginal zone lymphoma (SMZL) remain largely unclear.
  • While 7q deletion is observed in about 30% of SMZL cases, the specific gene affected is unknown.
  • Previous research indicated A20 inactivation in a small subset of SMZL, suggesting potential involvement of the NF-κB pathway.

Purpose of the Study:

  • To investigate the role of NF-κB pathway deregulation in the pathogenesis of splenic marginal zone lymphoma.
  • To screen key NF-κB regulators for genetic alterations in SMZL.

Main Methods:

  • Polymerase Chain Reaction (PCR) and DNA sequencing were employed to screen for somatic mutations.
  • Specific NF-κB regulators including A20, MYD88, CARD11, CD79A, CD79B, and ABIN1 were analyzed.

Main Results:

  • Somatic mutations were identified in A20 (13%), MYD88 (13%), and CARD11 (8.8%).
  • No mutations were found in CD79A, CD79B, or ABIN1.
  • The observed genetic alterations, particularly MYD88 mutations, were largely mutually exclusive with each other and with 7q deletion.

Conclusions:

  • Deregulation of the toll-like receptor (TLR) and B-cell receptor (BCR) signaling pathways is strongly suggested to be crucial in SMZL pathogenesis.
  • Mutations in A20, MYD88, and CARD11 point towards the involvement of these key signaling pathways in the development of splenic marginal zone lymphoma.

Related Concept Videos

Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...